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Summary
Substance P (SP), a neurotransmitter, may play an important role in neurogenic inﬂammation. Ginseng has
been used extensively in traditional medicine; however, few studies were focused on their anti-allergic eﬀect.
Therefore, the eﬀect and mechanism of ginsenoside Rb1 on the SP enhancement of allergic mediators were
explored. In this study, SP and dinitrophenyl-bovine serum albumin (DNP-BSA) were used to activate rat
basophilic leukemia (RBL)-2H3 cells. The cultured supernatants were assayed for histamine, leukotriene
C4(LTC4) and interleulin-4 (IL-4) production. The mitogen-activated protein kinases (MAPKs) signaling
pathway was determined by Western blotting analysis. We found that IgE/DNP-BSA, SP, ginsenoside Rb1,
or MAPK speciﬁc inhibitors had no eﬀect on cell viability and cytotoxicity. SP (30 lM) alone, did not
induce histamine and LTC4 release, but it enhanced allergen-induced histamine and LTC4 release.
In addition, SP signiﬁcantly induced and enhanced allergen-activated IL-4. Ginsenoside Rb1 dose-
dependently inhibited these eﬀects. SP enhanced the allergen-activated ERK pathway in RBL-2H3 cells,
and Rb1 eﬀectively inhibited the ERK pathway activation. Although MAPK speciﬁc inhibitors suppressed
LTC4 and IL-4, only U0126 inhibited the SP enhanced histamine release. These results demonstrate that
Rb1 dose-dependently inhibited SP enhanced allergen-induced mediator release and its mechanism was
through the inhibition of the ERK pathway.
Introduction
Neurogenic inﬂammation is orchestrated by a
large number of neuropeptides including tachyki-
nins such as substance P (SP) and neurokinin A, or
calcitonin gene-related peptide [1, 2]. SP and
neurokinin A, and its receptors are present in
human and animal airways [1, 3]. Local release of
tachykinins aﬀects blood vessels and broncho-
constrition and hyperresponsiveness. Tachykinins
are important to mast cells, and they are chemo-
tactic for neutrophils and eosinophils [1]. SP can
stimulate histamine release from human mast cells
of bronchoalveolar lavage and enhance anti-IgE-
induced histamine release from rat peritoneal mast
cells [4, 5].
SP and neurokinin A, act through neurokinin
(NK)-1 and NK-2 receptors. NK-1 and NK-2
receptors are expressed in the lungs, and SP
is released in the airways of rat sensitized to
ovalbumin (OVA). The selective NK-1 or NK-2
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antagonists decreased OVA-induced late airway
responses in challenged animals [6]. On the other
hand, interleukin-4 (IL-4) and IgE-dependent mast
cell activation play important roles in allergic
airway inﬂammation [7, 8] and leukotriene (LT)
induce contraction of the human airway smooth
muscle, chemotaxis and increased vascular perme-
ability [9–12]. These mediators play important
roles in asthma and allergic rhinitis. SP induces
LT-B4 and prostaglandin E2 in mice [13]. LT-
receptor antagonist, montelukast is eﬀective and
safe in the treatment of patients with asthma and
allergic rhinitis [9].
Ginsenoside Rb1 from Panax ginseng (Aralia-
ceae) has a partial neurotrophic and neuroprotec-
tive role in dopaminergic cell cultures under
glutamate stress [14]. Ginsenoside Rh2 and the
metabolite of Rb1 have anti-inﬂammatory activi-
ties to LPS-induced macrophages [15, 16]. Pre-
treatment with Rb1 signiﬁcantly decreased
histamine and LT in a dose-dependent manner
during mast cell activation [17]. Rh2 had the most
potent inhibitory activity on beta-hexosaminidase
release from rat basophilic leukemia (RBL) cells
and in the passive cutaneous anaphylaxis reaction
[15]. However, the eﬀects of SP and Rb1 on
signaling pathway of mast cells have not been
studied. Therefore, we were interested in studying
the signaling pathway of SP enhancement on
allergen-induced RBL-2H3 cells and the eﬀect of
Rb1 on this neurogenic inﬂammation model.
Materials and methods
Ginsenoside Rb1, anti-dinitrophenyl (DNP) IgE
monoclonal antibody, substance P and o-phthal-
aldehyde were obtained from Sigma (St. Louis,
MO, USA). Dinitrophenyl-bovine serum albumin
(DNP-BSA) was obtained from Calbiochem (San
Diego, CA, USA) and MAP kinase inhibitors,
SB203580, SP600125, and U0126 were obtained
from Biomol (Plymouth Meeting, PA, USA). Fetal
calf serum (FCS) was obtained from BIOLOGI-
CAL INDUSTRIES (Kibbutz Beit Haeme,
Israel). Penicillin, streptomycin, and Dulbecco’s
Modiﬁed Eagle’s medium (DMEM) were pur-
chased from GIBCO (Grand Island, NY, USA).
Mammalian protein extraction reagent (M-PER)
was obtained from PIERCE (Rockford, IL, USA).
Anti-phospho-p38, ERK, JNK, or b-actin
antibodies were purchased from Abcam (Cam-
bridge, UK).
Cell culture and mediator assay
The RBL-2H3 cell line was maintained in DMEM
supplemented with 10% fetal bovine serum (FBS),
100 U/ml penicillin and 100 lg/ml streptomycin at
37 C in a humidiﬁed incubator under 5% CO2.
Conﬂuent cultures were passed by trypsinization.
The RBL cells were seeded at 2 105cells/well. and
sensitized with 10 ng/ml of anti-DNP IgE for 1 h at
37 C. The cells were then washed with Hank’s
balanced salt solution (HBSS) buﬀer, incubated
with ginsenoside Rb1 or medium for 1 h at 37 C
and then stimulated with 10 ng/ml DNP-BSA plus
30 lM substance P for 30 min at 37 C. Histamine
content in the supernatant and in the cells was
measured by the o-phthalaldehyde ﬂuorometric
according to the procedure described by Yoshim-
ura et al. [18]. Histamine release (%) was expressed
as the percentage of total histamine content.
IL-4 and LTC4 content in culture supernatants
were determined by ELISA kits (R&D, Minneap-
olis, MN and Cayman chemical, Ann Arbor, MI,
USA; respectively). The absorbance at 410 nm was
determined using amicroplate reader (spectraMAX
340, Molecular Devices, Sunnyvale, CA, USA).
Western blot analysis
Cells were washed and protein extracted by using
M-PER reagent (Rockford, IL, USA). Lysates
were clariﬁed by centrifugation at 12,000  g for
15 min at 4 C. The protein content was deter-
mined with the aid of Bio-Rad DC Protein Assay
Kit. Equal amounts of samples were subjected to
SDS-PAGE using 10% running-gels. Proteins
were transferred into PVDF membrane and block-
ing with 5% non-fat milk 2 h at room tempera-
ture. To study the mitogen-activated protein
kinases (MAPKs) signaling pathway, the mem-
branes were then incubated overnight at 4 C with
anti-phospho-p38, ERK, JNK, or b-actin anti-
bodies. Membranes were then incubated for 2 h
with the appropriate horseradish peroxidase-
conjugated anti-IgG. Proteins were detected by
the ECL system (Amersham, Berkshire, UK) and
quantiﬁed by densitometric analysis (Digital
Image Analysis System, PDI, Huntington Station,
NY, USA).
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Statistical analysis
Results are expressed as mean ± standard error
of the means from at least three experiments.
Comparisons among several groups were per-
formed with non-parametric ANOVA. Compari-
sons between two groups were performed with the
student’s t-test. A value of p<0.05 was considered
statistically signiﬁcant.
Results
Eﬀect of SP on allergen-induced mediators
RBL-2H3 cells have been used for the study of
IgE-mediated degranulation, secretion of inﬂam-
matory mediators, such as histamine, LTC4 release
and IL-4 [19]. Our results were consistent with the
previous reports on DNP-induced mediator re-
lease. The DNP-BSA dose-dependently aﬀected
histamine, LTC4 and IL-4 release from RBL cells
with a sub-optimal concentration of 10 ng/ml IgE.
(data not shown). SP (0.001–30 lM) alone did not
induce histamine and LTC4 release, but it enhanced
allergen-induced histamine and LTC4 release from
RBL-2H3 cells. However, SP signiﬁcantly induced
IL-4 alone and with allergen (Figure 1).
Eﬀect of Rb1 on SP-enhanced mediator production
To investigate whether ginsenoside Rb1 has anti-
allergic activity, we used SP-enhancement of IgE/
DNP-activated RBL-2H3 cells for the study. We
found that Rb1 dose-dependently (50–100 lM)
inhibited histamine and LTC4 release far below
the levels induced by IgE/DNP-BSA. In addition,
Rb1 dose-dependently (20–100 lM) inhibited SP-
enhanced IL-4 secretion (Figure 2).
MAPK activation in RBL-2H3 cells
SP alone or IgE/DNP induced MAPK activation
in RBL-2H3 cells. SP dose-dependently enhanced
the IgE/DNP-activated ERK pathway more
prominently than p38 or JNK MAPKs (Figure 3).
U0126 speciﬁcally inhibited SP enhancement of
allergen-activated ERK and Rb1 dose-depen-
dently (20–100 lM) inhibited the activated
ERK1/2 pathway (Figure 4). Among MAPK
inhibitors (from 0.01 to 1 lM of concentrations),
U0126 inhibited SP enhanced IgE/DNP-activated
histamine release whereas SB203580 or SP600125
did not (Figure 5a). In contrast, all three inhibitors
inhibited SP-enhanced allergen-activated LTC4
and IL-4 in RBL-2H3 cells (Figure 5b, c).
Discussion
Symptoms of asthma/allergic rhinitis are induced
by inﬂammatory mediators, which are released
upon activation of mast cells by allergen-IgE
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Figure 1. Eﬀects of SP on the allergen-induced mediators
from RBL-2H3 cells. SP enhanced DNP-BSA (10 ng/ml)-
induced histamine (a), LTC4(b), and IL-4 (c) release from
RBL-2H3 cells (2  105) with a sub-optimal concentration of
10 ng/ml IgE. Histamine release was assayed by a ﬂuorometric
method, IL-4 and LTC4 by ELISA kits. Values represent
means from ﬁve separate experiments. *p<0.01 as compared
with the IgE/DNP group (mean ± SEM): histamine release
(20 ± 2%); LTC4(15 ± 5 lg/ml), and IL-4 (12 ± 2 lg/ml).
SP (lM): concentration in lM.
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interaction. These mediators target the end organs
directly or indirectly. For instance, stimulation of
sensory nerves by histamine may lead to sneezing,
pruritus, rhinorrhea, nasal congestion, and asth-
ma. These symptoms are characterized by the
phenomenon of hyperresponsiveness to non-
allergic stimuli, such as cold air and various
irritants and these symptoms may also cause by
allergic inﬂammation on the sensory nerves that
supply the upper airway [20, 21]. Therefore,
neurogenic inﬂammation involved airway and
other organs, is orchestrated by a large number
of neuropeptides including SP and neurokinin A
[22]. Allergic inﬂammation in turns, can induce
SP synthesis in large-diameter (A-ﬁber) ganglion
neurons innervating guinea pig lungs [23].
Although a recent study showed that SP induced
histamine release in human skin mast cells [24],
present result agreed with other studies that SP
alone did not induce histamine release but en-
hanced allergen-eﬀect in RBL cells [5, 25]. The
diﬀerence may be related to the allergic state of the
cells sources.
SP induces LTC4 release from murine mast
cells [26], but RBL-2H3 cells in our study did not.
The discrepancy may be due to the diﬀerent
sources of the mast cells, similar to the controversy
of histamine release [24, 25]. However, we found
that SP signiﬁcantly enhanced allergen-induced
LTC4 release. LTC4 and its metabolites are
extremely potent bronchoconstrition agents that
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Figure 2. Eﬀects of ginsenoside Rb1 on the SP enhancement
of allergen-induced mediators. Pretreatment (1 h) with Rb1
inhibited histamine (a), LTC4 (b), and IL-4 (c) release from
the SP enhancement of allergen-induced RBL-2H3 cells. Data
represent means ± SEM from ﬁve separate experiments.
*p<0.01 as compared with the SP/allergen group. Rb1 con-
centrations in lM: Rb 20: 20 lM; Rb 50: 50 lM; Rb100:
100 lM.
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Figure 3. Eﬀect of SP on enhancement of allergen-induced
MAPK pathway. RBL-2H3 cells were stimulated with
10 ng/ml IgE/DNP-BSA and substance P for 20 min at 37 C
and then were extracted and subjected to Western blotting as
described in the Materials and methods. The blotted mem-
branes were examined with anti-phospho-p38, ERK1/2, JNK,
or b-actin antibodies. Upper panel (a): representive blot re-
sults. Lower panel (b): densitometry data represented the
means from three experiments. *p<0.05 as compared with
the IgE/DNP group.
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are pathogenic in both asthma and allergy [10–12].
In addition, SP alone induced IL-4 similar to the
other report [27] and it enhanced allergen-induced
IL-4 from RBL-2H3 cells. Mast cell activation
provides a rapid and local pulse of IL-4 into the
local environment essential for the triggering of T
lymphocytes into sustained IL-4 production [28,
29]. Human mast cells storing IL-4 within the
granules are likely to have an important inﬂuence
during the initiation and maintenance of the
allergic response [30]. In corroborate with this, a
recent study with combined analyses of genetic
alterations in the IL-4/IL-13 pathway reveals its
actual signiﬁcance to the development of atopy
and childhood asthma [31].
Ginseng has long been used for enhancing
brain function, immunity and anti-inﬂammation.
Ginsenoside Rb1 potentiates the eﬀects of nerve
growth factor on nerve ﬁber outgrowth [32] and
increases choline uptake by the brain [33]. Previ-
ously, pretreatment of Rb1 (91 lM) had been
shown to decrease histamine and LT in allergen-
activated lung mast cells [17]. Just as expected, we
observed that Rb1 (20–100 lM) signiﬁcantly
inhibited histamine, IL-4, and LTC4 release from
SP-enhanced allergen-activated RBL-2H3 cells.
Thus, the suppression of Rb1 on SP-enhanced
inﬂammatory mediators may provide a new
approach for treating neurogenic inﬂammation.
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Figure 4. Eﬀect of Rb1 on SP enhancement of IgE/DNP-
induced MAPK activation. RBL-2H3 cells were pretreated
with Rb1 for 1 h and subjected to Western blotting analysis
for MAPK phosphorylation. Upper panel (a): representive
blot results showed that Rb1 (20–100 lM) and U0126 (1 lM)
speciﬁcally inhibited the SP enhancement of allergen-activated
ERK1/2. Lower panel (b): densitometry data represented the
means from three experiments. *p<0.05 as compared with
the SP/allergen group.
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Figure 5. Eﬀects of MAPK inhibitors on SP enhancement of
allergen-induced mediators from RBL-2H3 cells. Cells were
pretreated with U0126 (U), SB203580 (SB) and SP600125
(SP6) for 1 h and then assayed the mediators from SP en-
hanced IgE/DNP-activated cells. Suppression of histamine (a),
LTC4 (b) and IL-4 (c) release by inhibitors of MAPKs
are compared with each SP/allergen group. Data represent
means ± SEM from three experiments. *p<0.05 as com-
pared with the SP/allergen group.
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SP stimulated TNF- a production in rat peri-
toneal mast cells is involved with MAPKs signal-
ing pathways [33]. We found that SP or allergen
induced ERK, JNK and p38 MAP kinase path-
ways in RBL-2H3 cells and SP enhanced allergen-
induced ERK1/2 more prominently than other
MAP kinases. Our result shows that Rb1 dose-
dependently inhibited the activated ERK1/2 path-
way. Furthermore, all three inhibitors of MAP
kinases suppressed LTC4and IL-4 from SP-
enhanced RBL-2H3 cells. However, U0126 selec-
tively suppressed histamine release from the SP
enhanced cells. This suggests that the ERK sig-
naling pathway is more important to RBL-2H3
cells under SP and/or allergen activation. A
previous study showed that U0126 slightly reduced
OVA-induced release of histamine but signiﬁcantly
inhibited the release of LTs from guinea pig lung
fragments [34]. In contrast, a study with rat
peritoneal mast cells showed that p38 MAPK
and JNK, but not ERK, were induced 5 min after
exposure to SP and the speciﬁc p38 MAPK
inhibitor SB203580 abolished SP-induced increase
in TNF-a and reduced histamine secretion [35].
Exposure of human basophils to allergens results
in a rapid secretion of mediators such as
histamine, LTC4, IL-4 and IL-13 which involves
PI 3-kinase and the subsequent activation of p38
MAPK and ERK1/2 but not JNK [36]. These
diﬀerences in the activation of MAPK pathway
are possibly due to diﬀerent responses in cell types.
Nevertheless, these MAPK-activated mediators
are targets of current asthmatic therapy consisting
of anti-histamines, LT antagonists, anti-inﬂamma-
tory glucocorticoid, and humanized monoclonal
antibodies against IgE and IL-4 [37].
In summary, neurogenic factor such as SP
plays a role in enhancing the allergen-activation of
mast cells. Rb1 may exert their eﬀects by stabiliz-
ing nerves from secreting neuropeptides and
reducing neurogenic inﬂammation. Therefore, the
inhibitory eﬀects of Rb1 on neurogenic inﬂamma-
tion may provide an additional therapeutic strat-
egy for asthma.
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